Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Zepbound is a subcutaneous injection that needs proper storage and handling during travel. There are ways you can travel with Zepbound to ensure it remains safe and effective to use. Zepbound ...

Zepbound sales keep soaring, even as weight loss drug growth slows An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. - Image ...

GLP-1RA drugs, including Mounjaro and Zepbound, are administered weekly via injection and work by simulating hormones that curb appetite and slow digestion, promoting longer-lasting satiety.

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

patients will have to source their own syringes for the injections. The move is an escalation of the battle between Lilly and Novo Nordisk in the fast-growing obesity drugs market, where Zepbound ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide ... Eli Lilly's rival obesity therapy Zepbound (tirzepatide), which helped ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio ... pen and Rybelsus oral tablet for type II diabetes and as Wegovy injection for weight management. On Wednesday, Novo Nordisk reported ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...